Advancing cancer research one cell at a timeNow Available On Demand
Understanding cancer drug responses, efficacy and resistance using high-content screening and single cell ICP-mass spectroscopy
If you've already registered, please click here to log into the webcast.
Historically, cancer treatment has taken a ‘one size fits all’ approach. However, it’s clear that every cancer is different and being able to understand and anticipate differences in drug response, resistance, and efficacy of therapies at the cellular level may provide better treatment options.
In this webcast, our first presenter, Dr. David Andrews, will describe how personalized cancer treatment is being developed using high-content screening in a Chronic Lymphocytic Leukemia (CLL) disease model. His research involves establishing imaged based screening techniques that report on multifactorial drug-responses of primary patient cells with the goal of personalizing cancer treatment decisions and drug-response monitoring.
Our second speaker, Dr. Elizabeth New, will present her recent findings on the determination of elemental content of metal-based chemotherapies and nanoparticles in individual cancer cells using single cell–mass spectrometry (SC-ICP-MS) in order to better understand chemotherapy resistance as well as potential new therapies. Metal-based therapies are the most widely used class of drugs to treat cancers and quantification of their uptake to better understand interactions within an individual cancer cell can yield critical information on the effectiveness of the drug.
In this webcast, they discuss:
- How to generate chemoresponse data using high content screening.
- How artificial intelligence software was used to identify different cellular responses to drugs.
- Insights into how SC-ICP-MS can be used to quantify the uptake of metal-based chemotherapeutic agents in individual cultured cancer cells.
This webcast has been produced for PerkinElmer by Nature Research Custom Media, which operates independently of other Nature Research editorial departments. The sponsor retains sole responsibility for content. About this content.